drugset / Trial / NCT00272103
Itopride in Functional Dyspepsia:a Dose Finding Study
Phase 2/3
Completed
500 enrolled
Royal Adelaide Hospital
Knoll Pharmaceuticals, Germany (now Abbott) · collabUniversity Hospital, Essen · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study aims to determine the efficacy and optimal dose of the prokinetic itopride for the treatment of patients with functional dyspepsia. The study will test in patients with functional dyspepsia the hypothesis that itopride is superior to placebo with regard to the improvement of symptoms.
Timeline
- Start
- 2000-12
- Primary completion
- —
- Completion
- 2002-01
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itopride | Small molecule | 50 mg | — |
| Subject | Itopride | Small molecule | 100 mg | — |
| Subject | Itopride | Small molecule | 200 mg | — |